Understanding how obesity affects exercise response

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the impact of chronic inflammation on muscle function and exercise responses in obese individuals. Participants will undergo various assessments, including treadmill and strength tests, as well as muscle and fat biopsies to gather comprehensive data. The study focuses on adults aged 20 to 45 who are classified as obese, excluding those with certain health conditions that may interfere with the results. The findings could provide insights into how obesity influences physical performance and recovery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Obese men and women ≥ 20 and ≤ 45 years of age.

Exclusion Criteria:

* Diabetes or fasting plasma glucose \>126 mg/dL
* Anemia (female subjects hemoglobin of \<11 g/dl and male subjects hemoglobin \<12 g/dl)
* Active coronary artery disease or history of unstable macrovascular disease (unstable angina, myocardial infarction, stroke, and revascularization of coronary, peripheral or carotid artery within 3 months of recruitment)
* Renal failure (serum creatinine \> 1.5mg/dl)
* Chronic active liver disease defined as aspartate aminotransferase (AST)\>144 IU/L or alanine transaminase (ALT) \>165 IU/L)
* Oral warfarin group medications or history of blood clotting disorders.
* Smoking
* Pregnancy or breastfeeding
* Alcohol consumption greater than 2 glasses/day or other substance abuse
* Untreated or uncontrolled hypothyroidism
* Debilitating chronic disease (at the discretion of the investigators)

Where it's running

• Mayo Clinic in Rochester
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Ian Lanza, PhD — Mayo Clinic
• Study coordinator: Rachel Osland
• Email: Osland.Rachel@mayo.edu
• Phone: 507-255-8112

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mechanical ventilation strategy to protect the lungs in obese adults during laparoscopic or robotic surgery

  This trial tests whether a specific intraoperative PEEP approach that uses transpulmonary pressure to limit lung power can improve breathing after surgery for adults with BMI 35 or higher undergoing laparoscopic or robotic procedures.

  Recruiting The University of Texas Medical Branch, Galveston · Galveston, Texas · NCT07774065

• Combined resistance training and high-protein diet to help frailty in sarcopenic obesity women

  This trial tests whether adding supervised resistance exercise to a high-protein diet helps frailty in obese, sarcopenic women.

  Recruiting Cairo University · El-Sheikh Zayed City · NCT07627919

• SA030 Injection in Adults with Overweight or Obesity (Phase 1)

  This first-in-human study tests a single dose of SA030 to see if it is safe and well tolerated in adults who are overweight or obese.

  Recruiting at 2 sites Phase 1 Suzhou Siran Biotechnology Co.,Ltd. · Brisbane, Queensland and 1 other locations · NCT07479862

• Weekly injections of GIP (NNC0480-0389) plus amylin (cagrilintide) to see stomach side effects in adults with overweight or obesity

  This trial tests whether adding a GIP injection (NNC0480-0389) to weekly cagrilintide changes stomach-related side effects in adults with overweight or obesity.

  Recruiting Phase 1 Novo Nordisk A/S · Harrow, Middlesex · NCT07411560

• MB-1 vs placebo for weight and metabolic health in adults who are overweight or obese

  A study will test MB-1 to see if it helps adults who are overweight or obese lose weight and improve metabolic health compared to a placebo.

  Recruiting Arrae · London, Ontario · NCT07363148

• Testing HM17321 injections to find safe dose ranges in healthy and obese adults

  This study will try single and multiple doses of HM17321 injections in healthy adults and adults with obesity to see if they are safe and how the body processes the drug.

  Recruiting Phase 1 Hanmi Pharmaceutical Company Limited · Cincinnati, Ohio · NCT07219589

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.